Dr. Punit Marathe is currently the Vice President, Research, DMPK, Clinical Pharmacology and Toxicology at Agios Pharmaceuticals. In 2020, Dr. Marathe joined the faculty of Department of Pharmaceutics at University of Washington as affiliate professor.  Dr. Marathe over her expansive career assumed executive leadership at Bristol-Myers Squibb and Syngene International.  Dr. Marathe experiences have included characterizing ADME profile of lead candidates, establishing PK-PD relationships in animal disease models; projecting human pharmacokinetic profile and efficacious doses, guiding selection of doses for FIH studies, characterizing human ADME profile and understanding drug-drug interactions liabilities. Dr. Marathe has published over 100 publications and has presented at multiple national and international conferences.

Dr. Chad E. Beyer is currently CEO of Kures, Inc, a clinical-stage company focused on precision neuropsychiatry and addiction. Over 25 years of pharma drug development experience, Dr. Beyer had a successful career in discovering and developing novel, disease-modifying medications. Dr. Beyer was formerly CEO and SVP of R&D at Promentis Pharmaceuticals, and prior to joining Promentis, Dr. Beyer was SVP of R&D at a new migraine-focused company called Ariel Pharmaceuticals. During his career, Dr. Beyer participated in the submission of 34 INDs and contributed significantly to the commercialization and life-cycle management of two blockbuster medications: EffexorXR® and Pristiq®. Dr. Beyer holds a Ph.D. in Pharmacology & Toxicology from LSU Medical Center, an MBA from the Rutgers Business. Dr. Beyer has authored more than 70 manuscripts and co-edited 2 books.